These results indicate ITGA1, ITGA2 or TEAD1 as a potential independent prognostic marker in distinguishing PCa patients who are classified with the intermediate risks, representing the most difficult patient group in clinic to avoid the overtreatment. The gene discussed is ITGA1; the disease is posterior cortical atrophy.